Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with an increased risk of gallbladder disease, particularly with prolonged use and higher doses.
- GLP-1RAs improve glucose control and facilitate weight loss by enhancing insulin secretion and reducing glucagon release.
- They are effective for managing type 2 diabetes mellitus and obesity.
- Prolonged use and higher doses of GLP-1RAs may increase the risk of gallstone formation and inflammation of the gallbladder.
- Potential mechanisms for biliary disease include suppression of cholecystokinin and alterations in gut-brain pathways.
- A novel algorithm is proposed to outline strategies for addressing the risks of biliary disease in patients using GLP-1RAs.
Simplified